Piomic Medical

Our Founder & CEO Christopher Hertz is presenting at Tech Tour Growth Health 2024 in Lausanne! Over the next days, he looks forward to exploring the latest breakthroughs in health tech. At Piomic Medical, we’re passionate about transforming wound care with innovative solutions, and we’ve recently achieved some significant milestones. Notably, we’ve received Medicare Category B approval for our sham-controlled MAVERICKS US IDE trial, which is already well underway. With participating sites ranked among the top U.S. and state hospitals, this study stands as the one of the most comprehensive wound care research efforts of the decade. The wound care market is undergoing rapid change, particularly with Medicare’s new guidelines for skin substitutes. We believe this is the perfect time to seize opportunities for even greater impact. We look forward to connecting with investors, partners, and global leaders who share our vision for advancing wound care. If you’re attending, let’s meet and discuss how we can shape the future of wound care together. #TechTour2024 #WoundCareInnovation #MedTech #HealthTech #USExpansion #FutureOfCare #COMS #Piomic

🚀 New Study Reconfirms COMS® Effectiveness and Gives Insights to Potential New Applications for Wound Care 🚀 We’re thrilled to announce that the August edition of the Journal of Wound Care (JWC) features a new study led by Dr. Jacques Neyens and Prof. jos schols in the Netherlands, further validating the remarkable results of our COMS® technology. 𝗞𝗲𝘆 𝗛𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀: Study Details: Real-world case series involving patients at the Expertise Centre for Wound Care (ECW) in Oosterhout. 𝗜𝗺𝗽𝗿𝗲𝘀𝘀𝗶𝘃𝗲 𝗥𝗲𝘀𝘂𝗹𝘁𝘀:  o  COMS® demonstrated impressive wound surface reduction, with positive effects across all wound types treated. 𝗘𝗮𝘀𝗲 𝗼𝗳 𝗨𝘀𝗲 & 𝗖𝗼𝗻𝗳𝗶𝗱𝗲𝗻𝗰𝗲: o  Highly Rated by Professionals: The technology received high marks for ease of use from healthcare professionals and nurses. o  Strong Confidence: Users, including experienced nurses and professionals, felt very secure and confident in applying the technology. 𝗜𝗻𝘀𝗶𝗴𝗵𝘁𝘀 𝘁𝗼 𝗣𝗼𝘁𝗲𝗻𝘁𝗶𝗮𝗹 𝗡𝗲𝘄 𝗔𝗽𝗽𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻𝘀 𝗳𝗼𝗿 𝗪𝗼𝘂𝗻𝗱 𝗖𝗮𝗿𝗲: o  Effective for inducing autolytic debridement when sharp debridement isn’t feasible. o  COMS® may be a valuable tool for wound bed preparation in therapies like skin grafts. o  Healing success in new indications such as treating pressure ulcers (PUs). A huge shoutout to Dr. Jacques Neyens, W. van Heusden, Dr. D. Van Veenendaal, and Prof. jos schols for their incredible work! 👏 👉 𝗥𝗲𝗮𝗱 𝘁𝗵𝗲 𝗳𝘂𝗹𝗹 𝗮𝗿𝘁𝗶𝗰𝗹𝗲 𝗵𝗲𝗿𝗲: https://lnkd.in/dqzTUapv #WoundCare #Innovation #Healthcare #COMSTechnology

A new study reconfirms the powerful synergistic effects of concurrent optical and magnetic stimulation (COMS). Furthermore, the study highlights that COMS effectively reduces aminoglycoside antagonism, offering significant benefits for patients with infected wounds undergoing electromagnetic regenerative treatment. A big thank you to our partners at National University of Singapore for their invaluable contributions to this groundbreaking research! Access the study findings to uncover the intricate cellular responses and their significance for electromagnetic regenerative medicine: https://lnkd.in/d2TmjfBv

On this fall-like rainy ⛈ ☔ day in Zurich, I am wrapping up my 23rd month Wyss Zurich, hoping to bring some rays of sunshine 🌞 in your day, as indeed boosted mine 😁 ❤️Visited ETH AI Center – happily done - with a top espresso ☕!! I paid a visit to Daniel Naeff and had the chance to see what an amazing space they have available for their startups 😊 looking forward to hearing more and start doing things together: co-create, co-design and collaborate - the 3Cs of the future of work put in action 😃 💙 21st Lunch and Learn 🍽 📚 @ Wyss Zurich with Martin Walti, COO at Piomic Medical - done!! Martin shared with us the interesting journey of Piomic's founding and growth, and shared insights into product development and regulatory challenges that they worked to overcome. Key takeaways: 👉 Develop a good understanding of your target market 👉 Establish a long-term strategy - regulatory, clinical and reimbursement activities 👉 Understand and accept that markets can change and adapt accordingly 👉 Choose consultants wisely 👉 Align your funding wisely from the right growth places 🧡 Founders Day at Google Campus organized by Swiss Startup Association – attended!!! Great learning and networking opportunity for me to engage with startup ecosystem players. Thanks again to Regula Bleuler for inviting us. https://lnkd.in/eMzZztW3 💚 Female Founders ♀ 7th Pitch Event  – attended!! Another fantastic stage where I could listen to very promising pitches by future #entrepreneurs from ETH Zürich, University of St.Gallen and more, while introducing Wyss Zurich. Thanks to Sybille Zimmermann and Isabelle Siegrist for involving us in the awesome venue of Swisscom Ventures. https://lnkd.in/e_hWeqHT   💛 Biopitch GALA – attended cheering up for our project Phire (aka ATLyphe AG) !!! Super well powered by Student Biolab Zurich, the evening run so fast, making new encounters Natascha Schill, Alessandro Franchini (great pleasure to meet you!!) and seeing well-known faces such as Andreea Loredana Cretu, Jessica Plucain, Liliane Brunner Halbach, all here to bridge academia and industry. https://lnkd.in/eZ3McFe2   💜 ETH Backpack series:🎭 Art of Sales and Marketing for startups – attended!! Happy to see so much participation and willingness to #giveback to the #community by former founders to support the younger generation https://lnkd.in/e__6XDHW    #woundcare #healingwounds #woundmanagement #healthtech #medtechinnovation #biotech #femalefounders #wysszurich #wysszurichprojects #eth #uzh #foundersexperience

Beaucoup de monde pour le 16ème congrès de la SAFW Romande sur L’approche palliative dans les soins de plaies! Un franc succès et merci à tous ceux qui nous font confiance et soutiennent notre projet de jeune entreprise #piomicmedical

Thrilled to meet with our CRO partner, Syntactx, Now Part of NAMSA, at EWMA this year. It's a pleasure to collaborate as they immerse themselves in the world of wound care with us. Excited for what we can achieve together! #woundcare #diabetes #DFU #clinicalstudy #IDE #COMS #MAVERICKS

We warmly invite you to join us at our booth during the EWMA conference in London. It would be our pleasure to meet with you and discuss the latest updates on COMS. We look forward to connecting with you there! #COMS #EWMA2024

𝐄𝐱𝐜𝐢𝐭𝐢𝐧𝐠 𝐔𝐩𝐝𝐚𝐭𝐞𝐬 𝐟𝐫𝐨𝐦 𝐏𝐢𝐨𝐦𝐢𝐜 𝐌𝐞𝐝𝐢𝐜𝐚𝐥'𝐬 𝐀𝐆𝐌 We're excited to share highlights from our Annual General Meeting with shareholders and special guest Beat Merz from New Harbor Venture Partners. Beat offered valuable insights on transatlantic fundraising in the medtech sector, improving our strategic outlook. 𝐇𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐬 𝟐𝟎𝟐𝟑  This past year was pivotal for Piomic. We completed a second Series A closing, adding experienced medtech co-investors despite tough fundraising conditions. Our COMS One® Therapy System received MDR certification from TÜV Süd, ranking it among the first 10% of newly regulated medical devices. Our U.S. subsidiary has advanced significantly, appointing a new president with over 20 years in wound care. Market research with over 190 healthcare professionals confirmed a clear need for COMS® therapy and a strong market potential for our upcoming U.S. launch. The 𝑀𝐴𝑉𝐸𝑅𝐼𝐶𝐾𝑆 study, the most comprehensive in its segment this decade, has drawn leading research centers, providing a solid foundation for future reimbursement and commercialization endeavors. 𝐎𝐮𝐭𝐥𝐨𝐨𝐤 𝟐𝟎𝟐𝟒 Looking ahead, data from the 𝑀𝐴𝑉𝐸𝑅𝐼𝐶𝐾𝑆 study will mark a turning point, paving the way for our Series B fundraising to support the De Novo FDA submission and the potential U.S. launch of COMS®. As we reflect on a year of milestones and look forward to 2024, we thank our dedicated team, shareholders, and partners. #Piomic #AGM #COMS #MedTech #fundraising #TransatlanticPartnership #woundcare

Thrilled to share insights from Piomic's presence at the recent Wound Specialist Day at the University Hospital Zürich! 🌟   Our participation offered a valuable platform to engage with leading experts in wound care, showcase our groundbreaking solution COMS One, and dive deep into the latest advancements in the field. This event highlighted the commitment of Switzerland's wound care community to improve practices and patient outcomes.   A heartfelt thank you to everyone who joined us, shared their knowledge, and contributed to the event. Your passion and commitment to advancing wound care are truly inspiring.   Let's continue to innovate and collaborate for a brighter future in WoundCare!   #PiomicMedical #WoundCareInnovation #WoundSpecialistDay #UniversitätsspitalZürich #HealthcareCollaboration #COMS  

Piomic Medical achieved a significant breakthrough in U.S. reimbursement with two new Category III CPT codes issued by the American Medical Association for COMS® therapy. Set to take effect on January 1st, 2025, these codes streamline reimbursement procedures for healthcare professionals, representing a major advancement in the U.S. commercialization strategy. Following the CMS Category B designation for Piomic’s pivotal IDE study called MAVERICKS, the newly acquired Category III CPT codes facilitate accurate reporting of COMS® therapy utilization in the U.S. This not only lays the groundwork for broader adoption but also positions Piomic for a comprehensive rollout upon FDA approval. Martin Walti, Chief Operations Officer at Piomic Medical, commented: "We are pleased with the issuance of two new Category III CPT codes by the American Medical Association for COMS® therapy, which is a further important step in our U.S. commercialization strategy.” As Piomic Medical gears up for the U.S. launch of the COMS® One therapy system targeting refractory diabetic foot ulcers, the recently obtained Category III CPT codes play a central role. This groundbreaking therapy addresses a patient group facing elevated amputation rates and substantial morbidity, underscoring the importance of this development in Piomic's strategic approach. Read the full press release here: https://lnkd.in/ddJCQi9i #CPT #woundcare #diabetes #DFU #COMS #MAVERICKS #clinicalstudy #IDE